ABSTRACT
Background Globally, low back pain (LBP) is associated with high economic costs due to healthcare expenditure and production loss. There is lack of evidence regarding this in low-and-middle-income-countries (LMICs), including South Africa. Thus, the study aimed to determine the economic burden of LBP from the providers perspective.
Methods We used a retrospective prevalence-based cost-of-illness methodology to estimate the direct medical cost of LBP. Direct medical costs constituted costs associated with healthcare utilisation in inpatient care, outpatient care, investigations, consultations, and cost of auxiliary devices. We used diagnostic-specific data obtained from hospital clinical reports. All identifiable direct medical costs were estimated using a top-down approach for costs associated with healthcare and a bottom-up approach for costs associated with inpatient and outpatient care.
Results The prevalence of CLBP was 24.3% (95% CI: 23.5 – 25.1). The total annual average direct medical costs associated with LBP was US$5.4 million. Acute LBP and CLBP contributed 17% (US$0.92 million) and 83% (US$4.48 million) of the total annual average direct medical cost, respectively. The per patient total annual average direct medical cost for acute LBP and CLBP were US$99.43 and US$1,516.67, respectively. The total average cost of medication per patient for acute and CLBP were US$82.53 and US$320.31, respectively. Overall, the outpatient care costs contributed the largest share (38.9%, US$2.10 million) of the total average direct medical cost, 54.9% (US$1.15 million) of which was attributed to NSAIDs and only 10% (US$0.21 million) of the total outpatient cost was due to rehabilitation. The total average cost of diagnostic investigations was estimated at US$831,595.40, which formed 15.4% of the average total cost.
Conclusion The economic burden of LBP is high in South Africa. Majority of costs were attributed to CLBP. Action should be taken to develop culturally validated cost-effective prevention measures to mitigate the burden of LBP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the University of KwaZulu-Natal College of Health Sciences (CHS Scholarship). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) (Ref No: BREC/00000205/2019) and the KwaZulu-Natal Department of Health Ethics (Ref No: KZ_201909_002). Gatekeeper permissions were sort from participating institutions prior to the commencement of data collection. To guarantee the anonymity of each participant, the names of respondents, their addresses or other identifying information were included in the questionnaires, but rather each participant was assigned a study ID which was only accessed by the researcher. There was no human participation in this study, as it was a retrospective study of hospital health records for low back pain patients who presented to the hospitals between 2018 and 2019, therefore, no participants consent was required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author’s email address Morris Kahere: mrrskhr{at}gmail.com
Data Availability
All data generated or analyzed during this study will be included in the published article.
